StockpollyBeta
Get App
Popularity #1,192
SRRK · NASDAQ · Biotechnology

Scholar Rock (SRRK)

Develops anti-myostatin antibodies for spinal muscular atrophy and other neuromuscular diseases.

$51.19
After hours−0.01 (−0.02%)
At close$51.20(+6.31%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue111000490504700
Gross profit−1−1−1000−490−50−4700
434758596469281125345102109
Research & development303442424850496250475258
131315171619285053455051
General & administrative13015000285053455051
Other expenses000000−490−50−4700
Operating income−44−48−58−59−65−69−77−112−104−92−102−109
1221032211−3−1
Interest income000000033434
Interest expense000000011325
Other non-operating income0−2−2−10−3−2−3−3−31−4
Income before tax−42−46−57−59−64−66−75−110−102−91−106−110
Net income from continuing operations−42−46−57−59−64−66−75−110−102−91−106−110
Net income−42−46−57−59−64−66−75−110−102−91−106−110
EPS, basic−$0.53−$0.61−$0.59−$0.60−$0.66−$0.67−$0.67−$0.98−$0.90−$0.74−$0.83−$0.84
EPS, diluted−$0.53−$0.61−$0.59−$0.60−$0.66−$0.67−$0.67−$0.98−$0.90−$0.74−$0.83−$0.84
Weighted average shares, basic8176969797100112113114115127131
Weighted average shares, diluted8176969797100112113114115127131
EBITDA−43−45−56−58−64−66−74−108−100−88−103−105
Depreciation & amortization111000000000
EBIT−44−46−57−59−64−66−75−109−101−88−103−105